Global law firm Baker McKenzie is pleased to announce that Veleka Peeples-Dyer, Chair of the North America Food and Drug Administration Practice and Co-Chair of the Global Regulatory Practice, has been short-listed for FDA Pharmaceutical Regulatory Attorney of the Year in the annual LMG Life Sciences Awards in recognition of her innovative work in the field.
Veleka focuses her practice on assisting clients with regulatory, compliance and enforcement matters for FDA-regulated products, including food, cosmetics, drugs and medical devices. She represents clients in research, pre-launch, launch, commercialization and licensing activities for first-in-class products and other innovative products. Veleka was recognized in 2018, 2019, and 2020 by LMG as a Life Sciences Star in the FDA Regulatory category.
Short-listed firms and individuals for the Annual Americas LMG Life Sciences Awards are selected following a nomination process and based on interviews and surveys of lawyers active in the sector. Winners of the 2021 awards will be announced at the live ceremony on September 22 at Essex House in New York City.
About Baker McKenzie's Healthcare & Life Sciences Group
As one of the first law firms to advise life sciences companies on their global expansion 60 years ago, our deep knowledge in the industry, honed over the past six decades, is rooted in our corporate DNA. Our group is one of the largest of any international law firm, comprising over 800 lawyers in 47 countries. Many of our team members dedicate more than 50% of their time to industry clients― including in the top 10 largest healthcare and life sciences markets in the world.Our client base comprises big pharma, biotech, medical device companies, medtech and digital health companies, CROs, healthcare information providers, hospital systems, universities, non-profit institutions, veterinary drug companies and other service providers/companies in the life sciences and healthcare ecosystem. We have worked on a broad range of products and breakthroughs for clients, including complex and innovative collaboration and strategic alliance structures for new technologies, drugs, biologics, biosimilars and devices, in areas such as nanotechnology, cell and gene therapy and editing, vaccines and other drug development, as well as medical foods, dietary supplements, and other consumer products that are regulated by the FDA.